Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 7.07
Day High 7.46
Open:7.46
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

FEATURE-EMPTY
Description
Windtree Therapeutics, Inc. is a biotechnology company focused on developing novel surfactant therapies for respiratory diseases and other potential applications. The company's proprietary technology platform includes a synthetic, peptide-containing surfactant that is structurally similar to endogenous pulmonary surfactant and novel drug-delivery technologies being developed to enable noninvasive administration of aerosolized KL4 surfactant. Windtree Therapeutics, Inc., formerly known as Discovery Laboratories Inc., is based in Warrington, Pennsylvania.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Windtree to Host Company and Business Update Conference Call on June 4, 2020
- PR Newswire - PRF - Thu May 28, 7:00AM CDT
PR Newswire - PRF - CMTX
Thu May 28, 7:00AM CDT
, /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases,today announced it will host a conference call and webcast, including a slide presentation, at , June 4, 2020 to provide Company and business updates, including the recently announced completion of a public offering and up listing to The Nasdaq Capital Market, as well as updates on its acute cardiovascular and pulmonary clinical programs.
Windtree to Host Company and Business Update Conference Call on June 4, 2020
- PR Newswire - Thu May 28, 7:00AM CDT
PR Newswire - PRNW
Thu May 28, 7:00AM CDT
WARRINGTON, Pa. , May 28, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases,   today announced it will host a conference call and webcast, including a slide presentation, at 10:00 AM EDT on Thursday , June 4, 2020 to provide Company and business updates, including the recently announced completion of a $23 million public offering and up listing to The Nasdaq Capital Market, as well as updates on its acute cardiovascular and pulmonary clinical programs.
Windtree Therapeutics Announces Closing of $23 Million Public Offering Including Full Exercise of Over-Allotment Option
- PR Newswire - PRF - Fri May 22, 3:05PM CDT
PR Newswire - PRF - CMTX
Fri May 22, 3:05PM CDT
, /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the closing of its previously announced public offering of 2,758,620 units at a price to the public of per unit and the exercise in full of the underwriters' option to purchase 413,793 additional shares of common stock and 413,793 additional warrants. Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of per share. The warrants are exercisable for five years from the date of issuance. The common stock and warrants were immediately separable from the units and were issued separately.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 4.00 +80.50% increase
on 04/30/20
Period Open:9.90
Price movement based on the high, low and last over the given period.
9.90 -27.07% decrease
on 04/30/20
-2.68 (-27.07%) decrease
since 04/28/20
3-Month 4.00 +80.50% increase
on 04/30/20
Period Open:12.00
Price movement based on the high, low and last over the given period.
12.00 -39.83% decrease
on 03/04/20
-4.78 (-39.83%) decrease
since 02/28/20
52-Week 4.00 +80.50% increase
on 04/30/20
Period Open:11.85
Price movement based on the high, low and last over the given period.
14.97 -51.77% decrease
on 12/31/19
-4.63 (-39.07%) decrease
since 05/29/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies